Published in J Neuroinflammation on August 15, 2008
Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm (2013) 1.43
CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation (2011) 1.27
Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol (2009) 1.12
Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling. J Neuroinflammation (2014) 1.04
Small interfering RNA-mediated suppression of Ccl2 in Müller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration. J Neuroinflammation (2012) 0.98
Early focal expression of the chemokine Ccl2 by Müller cells during exposure to damage-inducing bright continuous light. Invest Ophthalmol Vis Sci (2011) 0.96
TNFα levels and macrophages expression reflect an inflammatory potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine. PLoS One (2013) 0.93
CCL2 modulates cytokine production in cultured mouse astrocytes. J Neuroinflammation (2010) 0.90
The role of IL-1β and TNF-α signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. Brain Behav Immun (2014) 0.89
Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol (2012) 0.88
Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1. Brain Behav Immun (2012) 0.88
Proinflammatory activity and the sensitization of depressive-like behavior during maternal separation. Behav Neurosci (2011) 0.87
The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis. J Neuroinflammation (2012) 0.86
Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice. Respir Res (2009) 0.85
Plasmodium genetic loci linked to host cytokine and chemokine responses. Genes Immun (2014) 0.85
DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am J Pathol (2009) 0.84
Astrocyte- and endothelial-targeted CCL2 conditional knockout mice: critical tools for studying the pathogenesis of neuroinflammation. J Mol Neurosci (2009) 0.84
Peripheral Administration of Tumor Necrosis Factor-Alpha Induces Neuroinflammation and Sickness but Not Depressive-Like Behavior in Mice. Biomed Res Int (2015) 0.83
General anesthetics inhibit LPS-induced IL-1β expression in glial cells. PLoS One (2013) 0.81
Prenatal stress is a vulnerability factor for altered morphology and biological activity of microglia cells. Front Cell Neurosci (2015) 0.80
Antibody-enhanced microdialysis collection of CCL2 from rat brain. J Neurosci Methods (2011) 0.80
The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice. Eur J Pharmacol (2015) 0.80
Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res (2017) 0.80
Differential Cytotoxicity but Augmented IFN-γ Secretion by NK Cells after Interaction with Monocytes from Humans, and Those from Wild Type and Myeloid-Specific COX-2 Knockout Mice. Front Immunol (2015) 0.78
CCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function. Oncotarget (2016) 0.77
Novel Therapeutic Targets in Neuroinflammation and Neuropathic Pain. Inflamm Cell Signal (2015) 0.77
Central CCL2 signaling onto MCH neurons mediates metabolic and behavioral adaptation to inflammation. EMBO Rep (2016) 0.75
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
The biology of chemokines and their receptors. Annu Rev Immunol (2000) 9.81
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 5.67
Biological basis of the behavior of sick animals. Neurosci Biobehav Rev (1988) 5.03
Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol (2003) 4.76
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature (1990) 4.46
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 3.81
Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev (1999) 2.77
Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol (2004) 2.60
Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci (2003) 2.52
Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab (2005) 2.45
Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci (2005) 2.41
Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J Neuroinflammation (2008) 2.25
MCP-1 protects mice in lethal endotoxemia. J Clin Invest (1997) 2.12
Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation (2003) 2.11
Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol (1995) 2.02
Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab (2003) 1.93
Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci (2004) 1.88
Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab (2002) 1.88
Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol (1999) 1.85
Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol (1998) 1.63
Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience (1998) 1.51
Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol (2004) 1.42
Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res (2003) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol (2007) 1.39
Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience (1996) 1.36
Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J Neuroimmunol (1995) 1.27
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J Leukoc Biol (2008) 1.25
Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administration. Cytokine (1992) 1.22
Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: comparison with interleukin-1 family and interleukin-6. Brain Res (1993) 1.18
Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res (2004) 1.15
Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur J Neurosci (2006) 1.15
Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol (1997) 1.14
Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem (1998) 1.11
Regulation of the gene encoding the monocyte chemoattractant protein 1 (MCP-1) in the mouse and rat brain in response to circulating LPS and proinflammatory cytokines. J Comp Neurol (2001) 1.10
Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in different models of systemic immune challenge. J Neuropathol Exp Neurol (1999) 1.06
Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res (2004) 1.05
Role of MCP-1 in endotoxemia and sepsis. Int Immunopharmacol (2008) 1.05
Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. Brain Res Mol Brain Res (2002) 1.04
Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist (2004) 1.04
Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats. J Cereb Blood Flow Metab (2004) 0.96
Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care (2004) 0.91
The chemokine CCL2 is required for control of murine gastric Salmonella enterica infection. Infect Immun (2005) 0.90
Combination treatment of neonatal rats with hypoxia-ischemia and endotoxin induces long-lasting memory and learning impairment that is associated with extended cerebral damage. Am J Obstet Gynecol (2004) 0.89
Cytokines and the immune-neuroendocrine network: What did we learn from infection and autoimmunity? Cytokine Growth Factor Rev (2007) 0.88
Localization of macrophage inflammatory protein: macrophage inflammatory protein-1 expression in rat brain after peripheral administration of lipopolysaccharide and focal cerebral ischemia. Neuroscience (1999) 0.85
Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei. J Neurosci Res (1999) 0.81
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Differential activation of astrocytes by innate and adaptive immune stimuli. Glia (2005) 1.99
IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol (2010) 1.73
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A (2003) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation (2008) 1.57
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging (2004) 1.42
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis (2005) 1.39
Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol (2010) 1.33
Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia (2007) 1.32
Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol (2009) 1.32
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation (2011) 1.25
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci (2004) 1.24
Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia (2006) 1.22
MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J Neuroimmune Pharmacol (2008) 1.20
Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia (2004) 1.19
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging (2004) 1.18
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets (2005) 1.16
Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol (2007) 1.16
S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem (2005) 1.13
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci (2004) 1.10
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis (2010) 1.09
The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci (2013) 1.08
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis (2011) 1.03
Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener (2011) 1.03
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J Neuroimmunol (2009) 1.02
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res (2009) 1.01
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation (2005) 1.01
Delta-like ligand 4 regulates central nervous system T cell accumulation during experimental autoimmune encephalomyelitis. J Immunol (2011) 0.99
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One (2013) 0.96
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. Curr Alzheimer Res (2005) 0.95
Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J Leukoc Biol (2004) 0.94
Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener (2014) 0.93
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domain. Exp Cell Res (2004) 0.92
Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. Ann Neurol (2004) 0.92
Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom (2003) 0.92
Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem (2002) 0.92
CCL2 transgene expression in the central nervous system directs diffuse infiltration of CD45(high)CD11b(+) monocytes and enhanced Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol (2003) 0.92
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
CC chemokine ligand 2 and its receptor regulate mucosal production of IL-12 and TGF-beta in high dose oral tolerance. J Immunol (2003) 0.91
CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function. J Leukoc Biol (2010) 0.90
The chemokine CCL2 is required for control of murine gastric Salmonella enterica infection. Infect Immun (2005) 0.90
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function. J Neuroimmunol (2011) 0.89
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol (2008) 0.88
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res (2006) 0.88
Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord (2013) 0.86
Inhibition of neuronal p38α, but not p38β MAPK, provides neuroprotection against three different neurotoxic insults. J Mol Neurosci (2014) 0.86
CCR2 regulates development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Viral Immunol (2007) 0.86
Early embryonic lethality of mice with disrupted transcription cofactor PIMT/NCOA6IP/Tgs1 gene. Mech Dev (2012) 0.85
Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes. Am J Physiol Heart Circ Physiol (2002) 0.85
Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front Biosci (2004) 0.84
Deficiency in p38β MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models. PLoS One (2013) 0.84
Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors. J Neuroimmune Pharmacol (2014) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
The C-terminus and linker region of S100B exert dual control on protein-protein interactions with TRTK-12. Biochemistry (2002) 0.84
Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors. Immunol Res (2002) 0.84
Hippocampal Sclerosis of Aging Can Be Segmental: Two Cases and Review of the Literature. J Neuropathol Exp Neurol (2015) 0.80
Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain. J Neuroinflammation (2013) 0.80
The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target. BMC Neurosci (2008) 0.79
CCR5 regulates high dose oral tolerance by modulating CC chemokine ligand 2 levels in the GALT. J Immunol (2004) 0.78
Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses. J Mol Neurosci (2002) 0.75